智飞生物(300122.SZ)：上半年净亏损5.97亿元

Core Viewpoint - The company reported a significant decline in revenue and a net loss for the first half of 2025, indicating financial challenges ahead [1] Financial Performance - The company achieved operating revenue of 4.919 billion yuan in the first half of 2025, a year-on-year decrease of 73.06% [1] - The net profit attributable to shareholders of the listed company was -599 million yuan, marking a shift from profit to loss compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -619.8 million yuan [1] - The basic earnings per share were -0.2494 yuan [1]